ASLAN 003

Drug Profile

ASLAN 003

Alternative Names: ASLAN003; LAS 186323

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.; ASLAN Pharmaceuticals
  • Class Antirheumatics
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Cancer
  • Discontinued Multiple sclerosis

Most Recent Events

  • 01 Mar 2015 ASLAN Pharmaceuticals completes a phase I trial in Rheumatoid arthritis (In volunteers, In the elderly) in Singapore (NCT02342652)
  • 01 Aug 2013 Phase-I clinical trials in Rheumatoid arthritis (in volunteers) in Singapore (PO)
  • 25 May 2012 No development reported - Phase-I for Multiple sclerosis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top